Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00273039 · ClinicalTrials.gov registry record · Phase 2
A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 242
- Enrollment target
NCT00273039 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 242 participants.
The verdict
NCT00273039, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 242 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and efficacy of GW679769 and paroxetine in subjects with Social Anxiety Disorder
Interventions
- DRUG paroxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2005-08 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00273039
The ClinicalTrials.gov registry entry for NCT00273039 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which paroxetine is the first listed.
NCT00273039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00273039 about?
NCT00273039 is a clinical study titled "A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder". The purpose of this study is to test the safety and efficacy of GW679769 and paroxetine in subjects with Social Anxiety Disorder
What is the current status of trial NCT00273039?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 242 participants. The study started on 2005-08. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00273039?
The interventions under investigation include: paroxetine (DRUG).
Who is sponsoring clinical trial NCT00273039?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.